The latest MRK stock forecast shows steady upside momentum, with analysts revising 12-month targets to $130–$135 amid robust Q1 earnings and strong pharmaceutical pipeline growth, particularly in oncology. Trading volume remains above its 30-day average, suggesting institutional accumulation. Average Analyst Price Target Upside as of August 16: 25.08% The Zacks Consensus Estimate for ABBV’s 2025 sales and EPS implies a year-over-year increase of 7.5% and 18.9%, respectively. EPS estimates for both 2025 and 2026 have risen over the past 30 days. Bullish MRK stock forecast scenarios emerge from new partnership deals in Asia-Pacific, expected to open fresh revenue channels in underpenetrated regions.
